Understanding the molecular etiology of prostate cancer (CaP) progression is paramount for broadening current diagnostic and therapeutic modalities. Current interest in the role of wnt pathway signaling in prostate tumorigenesis was generated with the ®nding of b-catenin mutation and corresponding nuclear localization in primary lesions. The recent ®nding of b-catenin-induced enhancement of androgen receptor (AR) function potentially ties b-catenin to key regulatory steps of prostate cell growth, dierentiation, and transformation. By immunohistological analysis of metastatic tumors, we detected nuclear bcatenin in 20% of lethal CaP cases, suggesting a more common role for b-catenin in advanced disease than would be predicted by its mutation rate. Interestingly, bcatenin nuclear localization was found to occur concomitantly with androgen-induced regrowth of normal rat prostate. These in vivo observations likely implicate b-catenin involvement in both normal and neoplastic prostate physiology, thus prompting our interest in further characterizing modes of b-catenin signaling in prostate cells. Extending our previous ®ndings, we demonstrate that transient b-catenin over-expression stimulates T cell factor (TCF) signaling in most CaP cell lines. Further, this activity is not subject to crossregulation by phosphoinositide-3-kinase (PI3-K)/Akt signaling, a stimulatory pathway often upregulated in CaP upon PTEN inactivation. Consistent with a previous report, we observed that transient b-catenin overexpression enhances AR-mediated transcription o two natural target gene promoters. However, we were unable to recapitulate b-catenin-induced stimulation of ectopically expressed AR in AR-negative cells, suggesting that other AR-associated factors are required for this activity. Although LNCaP cells are capable of this mode of AR co-stimulation, stable expression of mutant b-catenin did not alter their proliferative response to androgen. In total, our characterization of b-catenin signaling in CaP reveals the complex nature of its activity in prostate tissue, indicating that b-catenin potentially contributes to multiple stimulatory inputs required for disease progression.
Introduction
Prostate carcinoma is the most common non-cutaneous cancer aecting American men (Tindall and Scardino, 1999) . Although our ability to detect early stage tumors has increased, predictive diagnosis and eective tumor therapy remain limited, thereby incurring greater morbidity rates. Advanced CaP brought to remission with hormonal ablative therapy often relapses, leading to androgen-independent tumors for which only experimental treatments exist (Culig et al., 1998) . Urgently needed is a better understanding of CaP progression at the molecular level in order to reveal new targets for novel therapy design.
Several mechanisms underlying CaP progression have been described in molecular detail (Elo and Visakorpi, 2001) . Previous work and data presented herein implicate the wnt pathway and its eector signaling molecule, b-catenin, in this disease (Chesire et al., 2000; Voeller et al., 1998) . b-catenin mutations were detected at a rate of *5 ± 7% and shown to result in its accumulation and nuclear localization. b-catenin was originally identi®ed to participate in adherensmediated cell/cell adhesion, linking the cytoplasmic domain of E-cadherin to the actin binding protein acatenin (Takeichi, 1991) . Whereas E-cadherin and acatenin often exhibit altered expression in human cancer, b-catenin expression is rarely lost, implying that its signaling functions are important for cell viability. Soluble (cytosolic) b-catenin is subject to phosphorylation at its amino terminus by glycogen synthase kinase-3b (GSK-3b), prompting its ubiquitination and subsequent proteasomal degradation (Orford et al., 1997; Aberle et al., 1997) .
Binding of secreted wnt factors to the frizzled family of cell surface receptors initiates a signaling cascade leading to GSK-3b inhibition and alleviation of bcatenin repression (Miller and Moon, 1996) . Although growth factor-induced Akt activity can abrogate GSK3b function (Cross et al., 1995) , it is not clear whether or not b-catenin stabilization results (Ding et al., 2000; Yuan et al., 1999) . Under wnt signaling, soluble bcatenin levels accrue, eventually leading to its nuclear import and interaction with the TCF family of transcription factors. b-catenin de-represses TCF target gene expression, via recruitment of transcription factors such as Creb binding protein (CBP) and TATA binding protein (TBP) to its amino and carboxy terminal transactivation domains (Takemaru and Moon, 2000; Hecht et al., 1999) . Targets of the bcatenin/TCF bipartite transcription factor include the proto-oncogenes c-myc, cyclin D1 and matrix metalloproteinase (He et al., 1998; Tetsu and McCormick, 1999; Crawford et al., 1999) . Despite being less well characterized, b-catenin has also been shown to play a role in gene expression mediated by other transcription factors besides TCF (Easwaran et al., 1999; Truica et al., 2000; Palmer et al., 2001; Zorn et al., 1999) . To encompass this breadth of b-catenin involvement in gene transactivation, we employ the term CRT (bcatenin-related transcription), which was originally de®ned by Morin et al. (1997) to describe only bcatenin-TCF-regulated transcription.
Wnt signaling was originally discovered as a key regulator of tissue development and patterning in Drosophila, but more recently has been shown to play a role in several human cancers (Morin, 1999) . Indeed, CRT is associated with cell proliferation, survival, potency, and maintenance of undierentiated phenotypes (Korinek et al., 1998; Zhu and Watt, 1999; Orford et al., 1999; Ross et al., 2000) . Importantly, however, implications of its involvement in tissue dierentiation indicate that various inputs (molecular, temporal, morphological) shape the ultimate outcome of CRT signaling (DasGupta and Fuchs, 1999; Park et al., 1999; Hsu et al., 2001) . Although wnt factor overexpression is not clearly associated with tumorigenesis in humans, aberrant signaling can result from changes in b-catenin turnover. Mutation of the adenomatous polyposis coli (APC) gene product and axin, proteins required for GSK-3b recognition and phosphorylation of b-catenin, lead to b-catenin stabilization Satoh et al., 2000) . Similarly, direct mutation of b-catenin at Ser/Thr phosphorylation sites, or neighboring residues, results in its accumulation . Likely, b-catenin hyperactivation can result from alterations in other pathway regulators, such as the FRAT family of proteins and the F-box protein b-TrCP (Yost et al., 1998; Hart et al., 1999) . One hallmark of b-catenin signaling in both normal and neoplastic tissue is nuclear staining. However, the eects thereof may vary due to dierential expression of necessary cofactors and potential cross-regulation by other pathways.
Central to processes of prostate growth, dierentiation, and tumorigenesis is androgen receptor (AR) signaling (Culig et al., 1998; Cude et al., 1999) . Current models place inactive AR in the cytosol where, upon binding its ligand dihydrotestosterone, it undergoes a conformational change accompanied by nuclear translocation. In a homodimeric fashion, ligand-bound AR binds speci®c DNA elements in target gene promoter and enhancer regions, upregulating expression via recruitment of other transcription factors (e.g. p160 proteins) to its amino terminus (Cude et al., 1999) . Target genes include those related to both cell cycle progression (CDK2) and secretory function (kallikrein expression). Little is known to explain the functional dichotomy that exists with AR stimulation of cellular proliferation and transformation versus quiescence and dierentiation.
At present, blockade of AR activity through androgen ablation is one of the only eective treatments for managing advanced CaP. As relapse to androgen-independent disease is very common, attention has focused on coincident changes in AR expression and function. Several mechanisms, all of which are founded on resumption of AR signaling, have been proposed to explain progression to androgen-independence. Missense mutations in the ligand binding domain can impart promiscuous behavior to AR, often resulting in its nuclear induction by female steroids and certain anti-androgens used for ablative therapy (Cude et al., 1999) . Such mutations, and increased AR levels resulting from gene ampli®cation (Linja et al., 2001) , may restore androgen sensitivity to metastatic prostate tumor cells in an otherwise androgen-scarce milieu. Phosphorylation of AR may result in ligand-independent signaling, essentially bypassing the classical mode of activation. Extracellular signaling factors, such as insulin-like growth factor-I (IGF-I) and interleukin-6 (IL-6), have been clinically and functionally linked to this form of AR modi®ca-tion in cancer (Culig et al., 1994; Lin et al., 2001) . Likewise, intracellular signaling mediated by protein kinase A (PKA) and Akt have been shown to upregulate ligand-independent AR activity in this fashion (Sadar, 1999; Wen et al., 2000) .
Distinguishing between the eects of signaling pathways on CaP progression mediated by either ARdependent or AR-independent mechanisms is of great importance for future therapy design. It is possible that some forms of AR-independent signaling elicit the same response as an AR-dependent signal (e.g. gene activity, growth phenotype). Such redundant downstream events may render androgen ablative therapies more tenuous, and therefore more focus should be drawn to inhibition of upstream oncogenic activities. For example, are the oncogenic eects of PTEN inactivation derived from consequent Akt-mediated AR phosphorylation, or rather from Akt phosphorylation of other targets leading to increased cell survival? With these ideas in mind, we wished to examine facets of b-catenin signaling in CaP cells to evaluate its contribution to disease progression in vivo. Results shown here, along with previous work (Chesire et al., 2000) , directly implicate b-catenin as a potential nuclear signaling factor in both neoplastic and rapidly dividing normal prostate epithelium. The function of bcatenin as a transactivator of TCF target gene activity b-catenin signaling in prostate DR Chesire et al to drive cell proliferation is well established. However, more recent evidence points to a role for b-catenin in ligand-dependent co-stimulation of AR activity in prostate cells (Truica et al., 2000) . Further understanding of these two modes of b-catenin signaling in CaP cells may not only lend support to existing models of tumorigenesis, but also reveal previously unrecognized strategies for growth selection.
Results

Nuclear localization of b-catenin in prostate cells
Previously, we had performed a mutation screen of bcatenin exon 3 and found activating mutations in primary cases (*5%) and one metastatic case (Chesire et al., 2000) . Immunostaining of these tumors demonstrated nuclear localization of b-catenin, suggesting that these mutations imparted greater signaling and CRT. Despite having found only one advanced case with mutation and positive nuclear staining (A17), other data revealing nuclear staining in melanoma tumors wild type for b-catenin prompted our further inquiry into the potential role of b-catenin in advanced CaP (Rimm et al., 1999) . To this end, we performed immunohistological analysis on our entire panel of metastatic tumors obtained at autopsy from individuals who failed hormonal ablation therapy. In addition to case A17, four other cases (A2, A5, A11, A15; Figure  1 ) were positive for nuclear localization, resulting in a positivity rate of *24% (5/21). In these cases, tumors at other metastatic sites likewise contained positive nuclei. Nuclear staining was heterogeneous, suggesting that b-catenin signaling may be subject to multiple inputs despite potential pathway aberrations. Additional mutation analysis of genomic DNA by direct sequencing of PCR products ruled out activating mutations in exon 3 as accounting for the observed nuclear b-catenin expression. Since ampli®ed fragments were of the predicted size (*950 bp, primers located in exons 2 and 4), we concluded that no large interstitial deletions had occurred which would have precluded successful sequencing of all ampli®ed fragments with internal primers. b-catenin signaling plays a key role in tissue growth and homeostasis through maintenance of proliferative potential in stem cell compartments (Korinek et al., 1998; Zhu and Watt, 1999) . Because of these observations and our discovery of putative CRT upregulation in both primary and advanced stages of CaP, we investigated b-catenin activity in normal prostate growth. To address this question, we took advantage of the well characterized model of involution and regrowth of the rat ventral prostate (Sandford et al., 1984; Kerr and Searle, 1973) . Using this model, adult rats were castrated to commence a 2 week period of prostate involution followed by testosterone-induced gland restoration. As expected, glands from intact animals contained tall columnar epithelia while glands of castrated animals exhibited marked atrophy ( Figure   2a ). Although b-catenin was localized predominantly to cell/cell borders in glands of intact animals, it was distributed between both cell/cell borders and cytoplasm in glands of castrated animals. Most interestingly, b-catenin displayed nuclear localization in glands of testosterone-restored animals (4=24 h treatment). This staining pro®le paralled increased Ki67 staining, suggesting that b-catenin may be involved in androgeninduced prostate regrowth (Figure 2a) . Androgen receptor was markedly upregulated by 12 h post testosterone treatment (data not shown).
To better understand the mechanism of androgeninduced b-catenin upregulation in vivo, we examined the eects of androgen on b-catenin metabolism in AR-positive CaP cell lines (CWR22-Rv1, LAPC-4) by immuno¯uorescence microscopy ( Figure 2b ). As expected, androgen treatment elicited increased AR nuclear accumulation, consistent with our observation of androgen-induced promoter upregulation (see Figure 
b-catenin signaling through TCF transactivation
Our observations of nuclear b-catenin in prostate growth and carcinoma implicate its signaling as necessary for prostate cell growth and/or survival. To better understand the mode(s) of signaling b-catenin orchestrates, we analysed its activity in the contexts of either TCF-or AR-based target gene expression Truica et al., 2000) . Certain CaP cell lines are capable of supporting b-catenin nuclear translocation and TCF-based CRT, as shown by immuno¯uorescence and reporter studies (Chesire et al., 2000) . We determined the fold activation of a synthetic b-catenin/TCF-responsive luciferase reporter (pOT) upon ectopic expression of wild type or mutant (Del, D24-47) b-catenin in a broader array of CaP cell lines ( Figure 3a) . As expected from previous work, the mutant form was more potent in reporter activation compared to wild type protein, suggesting that mechanisms of b-catenin downregulation are intact in these cells.
Others have shown that the cyclin D1 promoter contains TCF-binding elements that endow its partial regulation by b-catenin (Tetsu and McCormick, 1999) . Similar to results obtained with the arti®cial promoter construct (pOT), our experiments demonstrate cyclin D1 promoter (71009 bp) stimulation by b-catenin (data not shown), further arguing that wnt pathway genes can be targeted in CaP.
The variation in induction among the cell lines may result from involvement of b-catenin in alternative pathways or from dierences in requisite signaling molecules. Despite reports of TCF4 expression being restricted to gastrointestinal and mammary tissues , we have observed its expression in a panel of normal and neoplastic specimens by cDNA microarray analysis (Luo et al., 2001) . Therefore, we examined properties of TCF4 expression in CaP cell lines, as such may greatly impact CRT. Western blot analysis demonstrated moderate expression of TCF4 in TSU, DU145, PC-3, CWR22-Rv1, and LAPC-4 cells ( Figure 3b , data not shown). However, TCF4 expression in LNCaP cells was low, perhaps explaining their poor b-catenin transactivation potential. We observed two TCF4 isoforms (*86 and 64 kD), perhaps resulting from either alternative splicing events (Roose and Clevers, 1999; Duval et al., 2000) or from posttranslational modi®cation (Ishitani et al., 1999; Sachdev et al., 2001) . The latter possibility seems more plausible, since the ORF of the longest TCF4 splice form in the GenBank database (accession CAA72166) encodes a peptide of *68 kD, far short of 86 kD. Calf intestinal phosphatase treatment (CIAP) of immunoprecipitates veri®ed that TCF4 is phosphorylated, but does not account for the molecular weight dierence between the two isoforms ( Figure 3c ). This observation is interesting, as the only known mechanism of TCF4 phosphorylation, and its consequent inhibition, is through MAP kinase signaling to TGF-b-activated kinase (TAK) (Ishitani et al., 1999) . Sachdev et al. (2001) have recently shown that lymphoid enhancer factor-1 (LEF-1), a TCF4 homologue, is inhibited by covalent attachment of small ubiquitin-related modi®er (SUMO) proteins. Given that both TCF4 and LEF-1 share the same two sumoylation sites, and that SUMO protein (*11 ± 12 kD) addition would account for the molecular weight dierence between the TCF4 isoforms, there is a possibility that TCF4 is SUMOmodi®ed. In any case, it is important to note that SW480 (APC 7/7 ) colon cancer cells, which harbor constitutively high levels of TCF-based CRT , display the same TCF4 expression pro®le as CaP cells (Figure 3c , data not shown). Since TCF4 is the only TCF family member appreciably expressed in SW480 cells , we infer that the 86 kD TCF4 isoform in CaP cells likely contributes signi®cantly to CRT.
These cells exhibit low basal b-catenin/TCF4 interaction ( Figure 3d , columns 2, 6, 10 and 14), consistent with our observation of low basal nuclear activity ( Figure 3a , pOT + pCDNA only). Ectopic expression of mutant b-catenin (Del) led to increased Figure 7 ). Precipitates were resolved by 6% SDS ± PAGE, transferred and probed. b-Catenin was observed in TCF4 IP lanes (columns 1, 3, 5, 7, 9 and 11) with longer autoradiograph exposure. FL, full length; Del, Deletant (D24 ± 47) (Takemaru and Moon, 2000) . Interestingly, we found that DU145 cells express low levels of CBP (Figure 3b ), possibly explaining their modest induction.
Cross-regulation of b-catenin signal transduction
Since b-catenin nuclear localization and its consequent eect on gene expression may be selected in a subset of CaPs (Figure 1 ) (Chesire et al., 2000) , we were interested in whether or not other pathways commonly altered in this disease aect b-catenin signaling. Ecadherin (E-cad) expression is often downregulated in prostate tumorigenesis, yielding a more invasive phenotype (Umbas et al., 1992) . E-cad-mediated cell/ cell adhesion potentially modulates CRT by complexing b-catenin at the cell border (Sadot et al., 1998) . Although this mode of sequestration may account for lower (or total lack of) CRT induction in E-cad positive cells (PC-3, DU145, LNCaP) in comparison to TSU (E-cad negative), it cannot account for the robust CRT induction displayed by E-cad-expressing CWR22-Rv1 and LAPC-4 cells (Figure 3a) . These results are in line with our observation of nuclear staining in cells transiently transfected with b-catenin (LAPC-4 and CWR22-Rv1, Figure 2b ).
The PTEN tumor suppressor gene is commonly deleted in CaP (Ali et al., 1999) . As PTEN is a negative regulator of the phosphoinositide-3-kinase (PI3-K) pathway, it is surmised that downstream eects of PI3-K are important for CaP cell growth and survival. Growth factor signaling induces PI3-K activation, which indirectly upregulates Akt, a serine/ threonine kinase that modulates several protein substrates including GSK3-b (Figure 4a ) (Cross et al., 1995) . Since PTEN inactivation renders enhanced Akt activity in CaP cells (Wu et al., 1998) , we wished to test if Akt upregulates b-catenin signaling, presumably through alleviation of GSK3-b suppression. To provide a framework in which to ask this question, we demonstrated that TSU cells in either depleted or serum-free medium had no activated Akt (P i -473S; Figure 4b , columns 1 and 2), but serum-starved cells treated for 30 min with either fresh medium or 3.5 mM insulin did show activation (Figure 4b , columns 3 and 4). The PI3-K inhibitor Ly294002 (50 mM) substantially dampened Akt activation in cells treated with fresh medium (Figure 4b , column 5), but marginally for cells treated with insulin ( Figure 4b , column 6). With this data in mind, we tested the eects of seruminduced PI3-K/Akt activity on TCF-based CRT in TSU and CWR22-Rv1 cells (Figure 4c ). As various treatments did not alter basal activity (+pCDNA ®ller), we examined cells transiently transfected with wild type b-catenin (+WT b-catenin). Ectopic bcatenin expression may yield a more robust read-out for eects of Akt activation on CRT, if any. We observed no real change in signaling with addition of fresh medium on cells in depleted medium (Figure 4c , compare columns 1 with 5). Indeed, the trend here hints of signaling inhibition, which is opposite of what would be predicted with serum-induced Akt activation. Inhibition of the PI3-K pathway with either PTEN (WT) over-expression or Ly294002 did not cause a signi®cant drop in CRT (Figure 4c ; compare column 1 with 2 and 4, 5 with 6 and 8). Finally, despite its reported ability to inhibit wild type PTEN in a dominant-negative fashion, over-expression of inactivated PTEN (C124S) did not elicit an increase in CRT (Figure 4c ; compare columns 1 with 3, 5 with 7) (Wu et al., 1998) . These data, along with evidence that biochemical compartmentalization of PI3-K and wnt stimulatory events renders pathway-speci®c GSK-3b downregulation (Ding et al., 2000) , suggest that these pathways elicit distinct outcomes. It is interesting that fresh serum did not stimulate CRT, given that growth factor-induced tyrosine phosphorylation of junctional b-catenin increases its soluble levels (Playford et al., 2000; Muller et al., 1999) .
AR signaling enhancement by b-catenin
Aside from its putative role in upregulating TCF-based gene expression, b-catenin may contribute to prostate growth and tumorigenesis through stimulating other pathways. b-Catenin has recently been shown to enhance AR target gene expression in LNCaP and AR-transfected TSU cells, reportedly through its involvement in AR complexes (Truica et al., 2000) . Aberrant AR co-activation, along with AR gene ampli®cation and mutation, is theorized as an important event leading to conversion of androgendependent disease to the lethal, androgen-independent form (Culig et al., 1998) . Since this phenomenon potentially constitutes a major role for b-catenin in CaP, we wished to examine this interaction further. Upon transient expression of b-catenin in the ARpositive cells CWR22-Rv1 and LAPC-4, we observed ligand-dependent enhancement of AR activity on a PSA enhancer/probasin promoter-driven luciferase reporter (pBK-PSE-PB-luc, Figure 5a ). This increase was AR-dependent, as no reporter response to androgen was observed in AR-negative cells (TSU and DU145, Figure 5a ). Compared to wild type, mutant b-catenin (Del) was more potent in coactivation (CWR22-Rv1, Figure 5a ), suggesting that stabilized forms have a greater impact on AR signaling in vivo. Interestingly, we consistently saw that bcatenin-induced augmentation of AR function was greater in CWR22-Rv1 cells compared to LAPC-4 cells. Perhaps the AR mutation in CWR22-Rv1 cells, which may account for their greater fold response to androgen, predisposes to ampli®ed co-activation events. Indeed, this mutation, although present in the ligand binding domain, is theorized to enhance recruitment of auxiliary transcription factors to the AR amino terminus (McDonald et al., 2000) . On the other hand, expression dierences in factors that contribute to AR signaling may exist between CWR22-Rv1 and LAPC-4 cells. As charcoal-stripping may remove other signaling factors besides steroids, it is important to note that fold b-catenin co-activation was not aected when experiments were performed in a complete medium context (data not shown). This observation suggests that the mechanism for bcatenin-mediated AR co-activation is not subject to extracellular signaling events known to alter AR function. We wished to understand the prevalence of b-catenin co-activation of AR function; is it a global phenomenon, or rather limited to a few particular target promoters? Thus far, the only prostate-speci®c AR target promoter tested is that for probasin. Therefore, we examined the eects of b-catenin expression on androgen induction of a human kallikrein-2 (HK-2) promoter/enhancer reporter construct. Interestingly, we detected a ligand-independent rise in reporter activity in CWR22-Rv1 cells (Figure 5b ). This rise may not require AR, as we observed a ligand-independent increase of reporter function in TSU cells ( Figure  5b ). However, in dose response to androgen, b-catenin over-expression was associated with a greater incremental rise in R1881-induced activity in CWR22-Rv1 cells. These results are consistent with the proposal that b-catenin aects AR transcriptional activity in a universal fashion. Our observation of ligand-independent HK2 promoter/enhancer stimulation by ectopic bcatenin suggests that certain AR target genes are subject to multiple forms of regulation. As such, constitutive b-catenin nuclear function may sensitize certain target genes to androgen induction.
AR transient expression and activation
We next asked whether or not b-catenin stimulation of AR function could be recapitulated in AR-negative cells. Similar to AR in LNCaP, CWR22-Rv1, and LAPC-4 cells, we saw that transiently expressed wild type human AR in TSU and DU145 cells accrued upon androgen stimulation (Figure 6a , data not 
Proliferation of cells stably expressing mutant b-catenin
Thus far, we have demonstrated that b-catenin signaling, whether via TCF-or AR-based mechanisms, can occur in cultured CaP cells. Given our observations of nuclear b-catenin in prostate tumors and in growing prostate, we wished to test the eects of bcatenin signaling on cell growth. LNCaP cells most likely would not adequately model the eects of constitutive b-catenin/TCF target gene expression (see Figure 3) . However, because LNCaP cells do exhibit AR signaling enhancement by b-catenin (Truica et al., 2000) , they could potentially model the eect of bcatenin on androgen-regulated growth. We had previously generated stable LNCaP clones that constitutively express mutant b-catenin (Del) (Figure 7a , LNCaP-1, and -12). Interestingly, neither LNCaP-1 or 12 manifests clear nuclear accumulation compared to parental cells or non-expressing clone LNCaP-4 (Figure 7b ). Since TCF expression may be a requirement for b-catenin nuclear localization, LNCaP cells may be de®cient here due to their low TCF4 levels (Figure 3b) . Alternatively, the robust expression of Ecadherin in these cells may abrogate soluble levels of mutant b-catenin. Although this negative staining is in accordance with low TCF-based CRT in LNCaP cells, it is important to bear in mind that positive staining is not requisite for nuclear activity, as HCT-116 colon cancer cells (D45S-b-catenin) have constitutively high CRT despite absence of observable nuclear staining (Chesire et al., 2000; Shih et al., 2000) .
To test the eect of mutant b-catenin expression on LNCaP growth response to androgen, we performed MTS growth assays on cells treated with R1881 ( Figure 
Discussion
We have uncovered evidence that b-catenin may demonstrate a more pervasive role in both normal and neoplastic prostate cell physiology than previously recognized. Our immunohistological data predict that processes of b-catenin signaling contribute to prostate cell growth and survival. That nuclear b-catenin can exist under very dierent physiological contexts (normal and neoplastic tissues) may re¯ect its eclectic signaling capacity. Therefore, one focus of this report was to further characterize two known modes of bcatenin signaling in CaP, that via TCF or AR, in order to better understand their respective contribution to disease progression. To accomplish this goal, we analysed these signaling events in more cell lines (only a limited number are available to CaP researchers), considered potential cross-regulatory eects of a prominent CaP pathway (PI3-K/Akt/PTEN), and tested the mitogenic eects of b-catenin over-expression. Our study is the ®rst to demonstrate positive nuclear b-catenin staining in metastatic CaP, linking the wnt pathway to androgen deprivation therapy failure and consequent lethality. Previously, b-catenin was shown to contain putative activating mutations in approximately 5 ± 7% of all CaPs and to exhibit nuclear localization therein (Chesire et al., 2000; Voeller et al., 1998) . The mutations were discovered almost exclusively in primary lesions, except for a single metastatic case in which the mutation was likely derived from the primary tumor. Despite absence of detectable mutations in our panel of metastatic cases (except A17), we found nuclear localization of b-catenin at an unexpected rate of 20%. This result is not unprecedented, as others have observed nuclear staining in cancers bearing no activating mutations in b-catenin exon 3 (Rimm et al., 1999) . Little evidence for APC mutation in CaP exists, suggesting that alteration of other pathway components (e.g. axin, b-TrCP) and heretofore uncharacterized interacting factors may account for our observation. We propose that, given the putative discrepancy in the molecular etiology of bcatenin upregulation between primary and secondary CaPs, b-catenin may mediate distinct modes of signaling at dierent stages of tumor progression.
The ®nding of nuclear b-catenin at any stage of CaP tumorigenesis may link its signaling function to cell survival and proliferation. That nuclear translocation of b-catenin occurs during androgen-induced regrowth of rat prostate corroborates this notion. The mechanism underlying this phenomenon remains unknown, but may not result from direct eects of androgen on epithelia. Currently, there exists intense interest in de®ning stromal/epithelial cell interactions, since neoplastic development may rely on certain intercellular signaling networks. From such studies, Planz et al. (1998) proposed that, in response to androgen, ARpositive stromal cells may secrete keratinocyte growth factor (KGF) leading to epithelial cell stimulation. In a similar fashion, androgen may induce stromal cell secretion of wnt factor(s) which presumably would eect b-catenin upregulation in adjacent epithelia. Indeed, we did observe AR-positive stromal cells directly bordering epithelia (data not shown). On a separate note, it will be of interest to understand if bcatenin is involved not only in androgen-induced prostate regrowth, but also in the eventual growth quiescence presumably attained upon complete gland restoration. Underscoring this possibility is work demonstrating b-catenin involvement in growth/dierentiation cycles and a nearly exclusive role in the well dierentiated, glandular form of gastric cancer (DasGupta and Fuchs, 1999; Hsu et al., 2001; Park et al., 1999; Miyazawa et al., 2000) .
Several`pathway-speci®c' transcription factors are now known to act in multiple, seemingly distinct signaling cascades. For example, the SMAD family of proteins plays a central role in transducing TGF-b signals (Heldin et al., 1997) , but recent data demonstrate a broader signaling spectrum ranging from vitamin D receptor and TCF co-activation to AR repression (Yanagisawa et al., 1999; Nishita et al., 2000; Labbe et al., 2000; Hayes et al., 2001) . These ®ndings carry substantial rami®cations: signaling molecules execute a diverse array of events impacting both physiological and pathological mechanisms. Thus, the discovery of AR stimulation by b-catenin, on top of its already well characterized role in TCF transactivation, piqued our interest. Does b-catenin function in dierent capacities depending on when and where it signals in prostate (normal vs transformed)? In order to answer this question in a meaningful way, we further characterized these two modes of b-catenin signaling in widely utilized CaP cell lines.
Based on immuno¯uorescence work and luciferase reporter assays, we conclude that most CaP cell lines are able to exhibit b-catenin nuclear translocation and subsequent TCF target gene upregulation. Although not described in this report, the cyclin D1 promoter (71009) manifested a similar response to ectopic bcatenin as that observed with the arti®cial promoter. Therefore, we postulate that nuclear b-catenin may orchestrate expression of known TCF target genes in prostate cells in vivo, prompting cell division and survival. If the predominant function of nuclear bcatenin is to activate such gene expression, then it may feed into alternate physiologic pathways depending on tumor stage. For example, potential myc upregulation by b-catenin in low grade tumors may usually trigger p53-dependent apoptosis, yet may drive proliferation in more advanced tumors as already suggested by studies of myc gene ampli®cation (Bubendorf et al., 1999) . Such context-dependent events may explain the disparate rates of putative b-catenin activation between localized and metastatic disease.
Certain pathways independent of wnt may impact on b-catenin metabolism leading to increased target gene activity (Yost et al., 1998; Muller et al., 1999; Playford et al., 2000) . Inactivation of the PTEN tumor suppressor protein occurs frequently during CaP pathogenesis by chromosomal deletion and/or direct mutation (Ali et al., 1999) . Wu et al. (1998) have shown that, in prostate cells, loss of PTEN activity results in unchecked Akt activity. Despite the attractive hypothesis of b-catenin upregulation by Akt-mediated GSK-3b inhibition, our direct analysis indicates that these two pathways may be distinct from one another. Recent evidence supports this conclusion (Ding et al., 2000) , thus arguing for the importance of other Aktmediated events in CaP such as AR phosphorylation (Wen et al., 2000) .
Investigators over the last decade have recognized the necessity to regard cancers as tissue-speci®c diseases, thus bearing unique pathways of growth selection. Perhaps the ®nding of ligand-dependent AR stimulation by b-catenin re¯ects this assessment (Truica et al., 2000) . We have extended this body of work by demonstrating the same activity in CWR22-Rv1 (mutant AR) and LAPC-4 (wild type AR) cell lines, and that it likely functions globally on AR target promoters. However, we were unable to recapitulate AR co-activation by b-catenin in AR-negative cell lines. Although not described in this study, we were also unable to show speci®c b-catenin/AR interaction by IP analysis utilizing various antibody and detergent combinations, including those detailed by Truica et al. (2000) . In spite of these observations, multiple mechanisms may account for this novel form of AR stimulation. For example, b-catenin signaling via another DNA binding factor (e.g. TCFs) may heighten expression of a factor(s) capable of the observed activity. As myc has been shown to play an intimate role in expression of the AR gene itself (Grad et al., 1999) , its induction by b-catenin/TCF may impact on AR protein output. However, this idea is inconsistent with the observed lack of b-catenin/TCF signaling in LNCaP cells, given their reported ability to support bcatenin-enhanced AR function (Truica et al., 2000) . The apparent con¯ict of our results with those of Truica et al. (2000) , along with the implications posed by a report showing b-catenin co-activation of another nuclear receptor (RAR) (Easwaran et al., 1999) , mandates further inquiry of this potentially signi®cant mode of AR pathway cross-regulation.
The observation that b-catenin augments AR signaling in an androgen-dependent manner has important consequences with respect to interpreting nuclear b-catenin function in vivo. For example, under conditions imposed by androgen ablation therapy of metastatic disease, AR enhancement by b-catenin may not occur. Although upregulated b-catenin was shown to mollify the inhibitory eects of the anti-androgen bicalutamide on AR activity and to increase such activity elicited by an adrenal androgen (Truica et al., 2000) , b-catenin's contribution to metastatic tumors may lie solely in TCF target gene transactivation. This idea that alternate pathways can successfully substitute the growth/survival cues of AR signaling is plausible, et al., 2000) , whereas LAPC-4 expresses wild type AR (Klein et al., 1997) . TSU, DU145, and PC-3 cells are highly proliferative, ARnegative prostate cancer cells. It is important to note here that, during preparation of this manuscript, a report placing doubt on the origin of the TSU cell line was published (van Bokhoven et al., 2001) . Synthetic androgen (R1881) and PI3-K inhibitor Ly294002 were purchased from New England Nuclear (Boston, MA, USA) and Calbiochem (La Jolla, CA, USA), respectively. Insulin was purchased from Life Technologies. In all androgen treatment procedures, cells were incubated in media containing 10% charcoal-stripped FCS (CS-FCS, Cocalico Biologicals, Reamstown, PA, USA) for 48 h prior to addition of the same media (fresh) including R1881. Metastatic tumors were removed from various anatomical sites of autopsy cases and ®xed in phosphate-buered formalin. The deceased patients had failed hormonal ablation therapy and therefore these tumors represent the lethal, androgen-independent stage of advanced disease.
Control plasmids pGL3-Basic, pGL3-Control, pRL-CMV were from Promega (Madison, WI, USA) and utilized for both luciferase assay optimization and normalization (see below). The wild type b-catenin expression vector (pCI-wt-bcatenin) and b-catenin/TCF reporter constructs (pGL3-OT, pGL3-OF) were provided by Dr Ken Kinzler (Johns Hopkins University). pGL3-OT (herein referred to as pOT) consists of three optimal TCF binding sites upstream a basic promoter (TATA box) that drives ®re¯y luciferase expression. The bcatenin/TCF control reporter, pGL3-OF, which is comprised of pOT with mutated TCF binding sites, was used to judge background levels (data not shown). pCI-Del-b-catenin was used for expression of a mutant form (D24 ± 47) of b-catenin that lacks the GSK-3b phosphorylation target sites and exhibits constitutive nuclear activity (Chesire et al., 2000) . PTEN expression vectors (pCDNA-PTEN WT and C134S) were furnished by Dr Charles Sawyers (UCLA). Human AR expression was achieved with use of pCDNA-hAR. Brie¯y, a 3.2 kb fragment encoding hAR cDNA (Luke and Coey, 1994) was cloned into the multiple cloning site (NheI/BamHI) of pCDNA 3.1(7). Empty pCDNA 3.1(7) was purchased from InVitrogen (Carlsbad, CA, USA) and used to compensate for unequal CMV promoter levels in luciferase assays. Androgen-responsive ®re¯y luciferase reporter constructs (pBK-PSE-PB-Luc, pBK-HK-2-enhancer/promoterLuc) were provided by Dr Ron Rodriguez (Johns Hopkins University).
Antibodies were obtained from Transduction Laboratories (Lexington, KY, USA; b-catenin), Pharmingen (San Diego, CA, USA; AR), DAKO (Carpinteria, CA, USA; PSA), Calbiochem (a-tubulin), Upstate Biotechnology (Lake Placid, NY, USA; TCF4, CBP), New England BioLabs (Beverly, MA, USA; Akt, Phospho-Ser474-Akt), Zymed (South San Francisco, CA, USA; Ki67), Jackson ImmunoResearch Laboratories (West Grove, PA, USA; rhodamine-conjugated donkey anti-mouse IgG), and Pierce (Rockford, IL, USA; HRP-conjugated goat anti-mouse and anti-rabbit IgG).
Rat prostate regression and restoration
Male Copenhagen rats were obtained from Harlan Sprague Dawley (Indianapolis, IN, USA) and castrated as previously reported (Kyprianou and Isaacs, 1987) . Prostate involution, a consequence of both glandular cell apoptosis and atrophy (Kerr and Searle, 1973) , was allowed to progress for 2 weeks at which time testosterone-releasing implants were inserted subcutaneously (Kyprianou and Isaacs, 1987) . Time points of 0, 12, 24, 36, 48, 60 and 72 h were taken post testosterone restoration upon which pairs of animals were terminated and prostates removed. Tissue was ®xed in phosphate-buered formalin.
Immunohistochemistry and immunocytochemistry
Formalin-®xed tissues were embedded in paran and sectioned at 5 microns. Slides deparanized in xylene (twice for 5 min) were hydrated through a graded ethanol series (26absolute, 2695%, 1670% dipped until clear) and placed in deionized water followed by 1% Tween-20 (Sigma Chemical, St. Louis, MO, USA). Heat induced epitope retrieval (HIER) was utilized in unmasking antigen sites with the use of citrate buer (Vector, Burlingame, CA, USA). Slides were paired to form a capillary gap and placed into a steaming basket for 14 min. Slides were then air dried for 5 min and placed into PBS with Tween (PBST, Sigma). The detection of b-catenin and Ki67 was performed with the EnVision Plus System (DAKO) for monoclonal antibodies. The EnVision System provides biotin-free detection that utilizes an HRP labeled polymer eliminating the staining of endogenous biotin. Slides were incubated with hydrogen peroxide according to the EnVision kit instructions and blotted dry. Antibodies for b-catenin and Ki67, diluted 1 : 500 and 1 : 50, respectively, were incubated on slides for 30 min at room temperature. The slides were then rinsed with Tris buered saline with Tween-20 (TBST, Sigma) and incubated with the HRP conjugated secondary anti-mouse IgG for 30 min. As per the EnVision kit protocol, the chromagen diaminobenzidine was incubated on slides for 5 min. Slides were then rinsed in TBST, counterstained with hematoxylin, dehydrated through graded alcohols, cleared in xylene, and mounted with Cytoseal 60 mounting media (Stephens Scienti®c, Riverdale, NJ, USA).
Immunocytochemistry was performed essentially as reported (Chesire et al., 2000) . Diluted antibodies (PBS/3.75% BSA) were incubated with ®xed and permeabilized cells on two-chamber glass slides (Nunc, Naperville, IL, USA) at 1 : 250 (b-catenin) and 1 : 100 (AR). Slides were then treated with rhodamine-conjugated anti-mouse IgG (1 : 400), washed, mounted, and viewed under¯uorescence microscopy (AxioScope, Carl Zeiss, Thornwood, NY, USA). Images were documented using IP-Lab image-capturing software. For both staining procedures, non-speci®c background was monitored by treating specimens with secondary antibody only.
Immunoprecipitation, dephosphorylation and Western blot analyses
Cell lysates were prepared from subcon¯uent cultures by ®rst washing cells twice with cold PBS and then extracting with either RIPA (50 mM Tris 7.4, 0.5% DOC, 0.1% SDS, 1.0% NP-40, 150 mM NaCl, 1 mM EDTA) or NP-40 (50 mM Tris 7.4, 1.0% NP-40, 150 mM NaCl, 1 mM EDTA) detergent solutions. Protein concentrations of lysates were determined using a BCA kit (Pierce). All cell lysates and IP mixes contained a protease inhibitor cocktail obtained from Roche (Indianapolis, IN, USA). For IP analysis, equal amounts of protein in 300 ml total volume were incubated with antibody (concentrations: b-catenin, 1.5 mg/ml; TCF4, 3 mg/ml) or mouse serum (1 : 1000, Sigma) for at least 4 h at 48C. RIPA buer was used in IP of TCF4 for the dephosphorylation study (Figure 3c ), whereas NP-40 buer was used for TCF4/ b-catenin co-immunoprecipitation (Figure 3d ). Immunocomplexes were pulled down by addition of 75 ml buerwashed protein G+/A agarose beads (Oncogene Research Products, Cambridge, MA, USA), incubated at 48C for at least 2 h, and washed four times in the appropriate extraction buer. Prior to gel loading, SDS ± PAGE gel loading buer (Sambrook et al., 1989) was added to the beads and heated at 958C for 4 min.
For dephosphorylation assay, TCF4 immunoprecipitates (complexes on beads) were washed as above and then three times in CIAP reaction buer (50 mM Tris 8.5, 0.1 mM EDTA). After washing, beads were resuspended in 170 ml of the same buer to which 25 ml CIAP (1 u/ml, Roche) was added as appropriate. All reactions (+/7 CIAP) were incubated at 378C for 1.5 h after which the complexes were washed twice with RIPA buer and prepared for gel loading.
Techniques for running SDS ± PAGE and Western blots were as described (Sambrook et al., 1989) . Pre-stained molecular weight standards were purchased from Bio-Rad (Hercules, CA, USA). Upon completion of electrophoresis, proteins were transferred by Western blot to ECL nitrocellulose (Amersham-Pharmacia, Piscataway, NJ, USA) and blocked in 5% non fat-dried milk/PBS/0.1% Tween-20. Membranes were probed in blocking buer with antibodies at 0.5 mg/ml, washed, and probed with HRP-conjugated secondary antibody (anti-IgG). For appropriate blots, atubulin levels were also determined to verify equal loading. Enhanced chemiluminescence was performed with the ECL kit (Amersham-Pharmacia) followed by autoradiography.
Transfection, luciferase and proliferation assays
For luciferase assay experiments, cells were plated at medium density (10 000 ± 20 000 cells) to clear bottom, opaque-walled 96 well plates (Isoplate TC, Perkin Elmer Wallac, Gaithersburg, MD, USA). With those experiments involving androgen treatment, cells were given media/10% CS-FCS 24 h after plating (day 2), transfected (day 3), treated with R1881 (day 4), and analysed for luciferase activity (day 5). Transfections were performed using Fugene 6 Transfection Reagent (Roche) at 1 ml/0.2 mg DNA. On transfection day, media was replaced with 25 ml of the appropriate media, to which was added DNA/Fugene complexes in a total volume of *25 ml. Complexes were prepared such that every well received 50 ng reporter plasmid (encoding ®re¯y luciferase), 50 ng each appropriate expression plasmid and 10 ng pRL-CMV. To compensate for unequal DNA amounts between certain transfection groups, pCDNA 3.1 was included as appropriate. pRL-CMV, which encodes Renilla luciferase, was included in all mixes to allow for transfection normalization. For transient transfection with pCI-Del-b-catenin (Figure 3d ) and pCDNA-hAR (Figure 6a ), cells were transfected in 10 cm and six-well plates (Falcon, Franklin Lakes, NJ, USA), respectively. Media was replaced and cell lysates were prepared 1 and 2 days post transfection, respectively.
Luciferase assays were performed essentially as described using non-proprietary substrate/buer mixes (Dyer et al., 2000) . The substrates for ®re¯y and Renilla luciferase enzymes, luciferin and coelenterazine, respectively, were purchased from Biosynth AG (Staad, Switzerland). Cells were washed once in 100 ml PBS and then lysed in 30 ml 16Passive Lysis Buer (Promega), which permits optimal enzyme activity. Using the Wallac 1450 Microbeta Jet luminescence reader, ®re¯y and Renilla luciferase substrate mixes (100 ml) were injected sequentially, allowing 10 s activity readout for each enzyme. In this dual luciferase assay, ®re¯y luciferase activity is ®rst monitored under basic conditions. Then, an acidic, high salt buer is added that abolishes ®re¯y luciferase function, but permits Renilla luciferase activity. All experiments were repeated at least three times, and all samples were performed in quadruplicate. For normalizing each well, the ®re¯y luciferase value was divided by the Renilla luciferase value.
Cell proliferation assays were performed with the CellTiter 96 Aqueous One Solution Cell Proliferation Assay kit (Promega), which utilizes MTS instead of MTT. The number of live cells is proportional to the level of formazan-like compound produced from reduction of MTS by NAD(P)H. LNCaP cells (5000) were plated in clear 96-well plates (Falcon). Media was replaced 24 h later with that containing 10% CS-FCS and incubated with cells for 2 days. Then, media containing R1881 was given to the cells (100 ml) to commence androgen treatment. Measurements of relative cell number were taken by adding MTS reagent to wells, incubating cells for 1 h at 378C, and reading absorbance at 490 nm. Day 0 measurements were taken immediately following R1881 addition (single plate), and all measurements thereafter were taken at 24 or 48 h intervals (one plate for each day). No obvious cell death occurred throughout these experiments, implying that our analysis did not underestimate proliferation. These assays were duplicated and all samples were performed in 6 ± 7 wells each.
